Rocket Lab USA

Rocket Lab spent most of its public life as a one-trick pony: Electron, the dedicated small-satellite launcher, with a reliable cadence but a structurally capped revenue base of roughly $100 million per year. The 2026 story is fundamentally different because Neutron — the company's reusable medium-lift rocket aimed squarely at SpaceX's Falcon 9 market — finally crossed from PowerPoint slide to pad-tested vehicle. Neutron's inaugural launch is targeted for late Q3 2026 from Wallops Island, Virginia, with the first revenue-generating commercial flights scheduled for 2027. Even more importantly, Rocket Lab is no longer just a launch company. The Space Systems segment — which sells satellite buses, reaction wheels, solar arrays, and complete missions to defence customers — now generates more than 70% of total revenue. The trailing-twelve-month backlog stands above $1.1 billion, the highest in company history, weighted heavily toward US Department of Defense and Space Development Agency contracts. FY2026 revenue is guided to roughly $620 million, up 45% year-over-year, with the medium-term path to $2 billion in revenue dependent on Neutron entering operational cadence by 2028.

The smart-money base in Rocket Lab is unusual for a US growth name: heavy on specialist space and defence funds rather than generalist tech. Cathie Wood's ARK Space Exploration ETF (ARKX) holds Rocket Lab as a top-five position. Defence-focused hedge funds including Standard General and Atreides Management built positions through 2025 as the Space Force contract pipeline became visible. The most notable non-institutional holder remains founder/CEO Peter Beck, who owns roughly 11% of the float and has not sold a share since the IPO — a level of insider conviction extremely rare among SPAC-era space companies. On the other side, short interest remains elevated at 9% of float, concentrated in funds betting that Neutron slips by another year.

Rocket Lab trades at roughly 15× EV/forward-revenue and is not yet profitable on a GAAP basis. Compared with pre-IPO SpaceX private-market round implied multiples of 10-12× revenue, Rocket Lab looks expensive on a today-only basis. The bull case justifies the multiple via the Neutron optionality: if Neutron achieves a Falcon 9-style 20-30 launch cadence at 50% gross margins by 2030, Rocket Lab's implied 2030 EBITDA approaches $600M, against which today's ~$13 billion enterprise value looks reasonable at 22× forward EBITDA. Bull case fair value (Neutron flies on time, no failures, defence backlog grows to $2 billion): $35. Bear case (Neutron slips 18+ months or fails): $14.

1. August 7, 2026: Q2/2026 earnings — final guidance update before Neutron inaugural flight; backlog growth and Space Systems gross margin trajectory are the key tells.
2. September-October 2026: Neutron inaugural launch from Wallops Island, Virginia — the single most important binary catalyst in the company's history.
3. Q4 2026 / Q1 2027: Space Force Phase 3 launch contract awards — Rocket Lab is shortlisted alongside SpaceX, ULA, and Blue Origin; a Phase 3 win would add $1 billion+ to backlog.

I own a small position in Rocket Lab as an asymmetric optionality trade rather than a core holding. The bull case — Neutron operational, SDA backlog compounding, vertical integration scaling — would credibly produce a $50-plus stock by 2028. The bear case is a single bad flight that wipes out 40% in a day. That risk-reward only works if you size it correctly: this is not a 5%-of-portfolio name unless you have unusual conviction on Peter Beck's execution. Where I think consensus is wrong: most analysts underweight the Space Systems segment as a stand-alone defence supplier worth $4-6 billion even with Neutron failing. The downside is therefore likely smaller than the chart implies.